PICC Asset Management, established in 2003 and headquartered in Shanghai, is a prominent insurance asset management company in China, initiated by the China People's Insurance Group. With nearly 900 billion yuan in assets under management, it is authorized by regulatory bodies to engage in various investment activities, including stocks, bonds, real estate, and infrastructure. The company focuses on a comprehensive approach to asset management, emphasizing asset-liability matching and risk management. Over the years, PICC has diversified its offerings, engaging in third-party business development, special account management, and equity investments. It has built a robust portfolio that includes annuity and pension products while fostering partnerships with major financial institutions and enterprises. The firm is dedicated to professional growth and standardized operations, having established a tripartite deposit management mechanism to ensure investment security. By maintaining a strong resource base and a skilled professional team, PICC Asset Management aims to create long-term stable investment returns for its clients and position itself as a competitive player in both domestic and international markets.
UNISOC is a fabless semiconductor company specializing in the research and development of core chipsets for mobile communications and the Internet of Things (IoT). The company produces a wide range of products, including mobile chipset platforms that support various communication standards such as 2G, 3G, and 4G, as well as RF chipsets, wireless connection chipsets, security chipsets, TV chipsets, and image sensor chipsets. With a global workforce of over 4,500 employees and numerous research and development centers, UNISOC ranks among the top three suppliers of mobile baseband chipsets worldwide and is the largest pan-chip supplier in China. The company's offerings enable access to advanced technologies, including 5G and artificial intelligence, for consumer and industrial electronics.
Shanghai Desano Pharmaceuticals Investment
Venture Round in 2023
Desino was founded in 1996 and is headquartered in Shanghai Zhangjiang Hi-Tech Park. The company's anti-AIDS drugs and anti-malarial drugs are the core development areas for the global public health crisis, and are committed to the development, production, registration and global sales of high-quality drugs.The Dyson Company R&D Center is located in Shanghai and is the National Enterprise Technology Center, the National Anti-AIDS Drug Engineering Technology Research Center and the National Postdoctoral Research Station.
Asia Pacific Medical Group
Series A in 2022
Asia Pacific Medical Group operates a network of hospitals across Southeast Asia, focusing on both local and international patients. The group provides a comprehensive range of medical services, including neurology, oncology, cardiovascular medicine, pediatrics, dermatology, neurosurgery, plastic surgery, and tumor treatment therapies. Their facilities are designed to deliver inpatient healthcare services while ensuring affordability for patients seeking treatment. By offering specialized services such as gamma-knife treatment and cosmetology, Asia Pacific Medical Group aims to address various healthcare needs and enhance the quality of care available in the region.
Atech Automotive Electronics
Series C in 2022
Atech Automotive Electronics products are based on the generation of electronic and electrical architecture and the SOA concept and develop central core domain control, body controllers, domain controllers, Ethernet gateways, and radio frequency bluetooth. It is a company that designs, develops, manufactures, and sells automotive electronic products.
GAC Aion New Energy Automobile
Series A in 2022
GAC Aion New Energy Automobile is a Chinese manufacturer of electric vehicles, established in 2017 as a sub-brand of Guangzhou Automobile Corporation and officially launched as a marque in 2020. The company focuses on the development of new energy automobiles, aiming to deliver intelligent vehicles that enhance the driving experience for customers. GAC Aion emphasizes innovation and sustainability in its product offerings, contributing to the growing electric vehicle market in China.
Ingeek
Series B in 2022
Shanghai InGeek Cyber Security Co., Ltd, founded in 2002 and headquartered in Shanghai, China, specializes in information, network, and system security services. As a subsidiary of Shanghai Yinji Information Technology Co., Ltd, InGeek focuses on consulting, implementation, operation, maintenance, and software development related to cybersecurity. The company is committed to enhancing Internet of Things (IoT) security and provides industry-specific network information security products and comprehensive security solutions primarily for the communications, financial, and automotive sectors. InGeek aims to create a safer and smarter environment for connected vehicles, promoting innovation in technology while ensuring robust protection against cyber threats.
METiS Pharmaceuticals
Series B in 2022
Jitai Medicine (METiS) is a biotechnology company that uses artificial intelligence to drive drug delivery and drug discovery. It combines advanced technologies like artificial intelligence, machine learning, and quantum simulation to achieve more effective design of innovative delivery materials, drug candidate selection and formulation design, "programmable nucleic acid drug" development, and nucleic acid delivery design.
METiS Therapeutics
Series B in 2022
METiS Therapeutics is a biotechnology company that aims to drive therapies in a wide range of disease areas by integrating drug discovery and delivery with AI, machine learning, and quantum simulation.
ChangXin Memory Technologies
Venture Round in 2022
ChangXin Memory Technologies focuses on the development and manufacture of dynamic random-access memory (DRAM) semiconductor products. The company specializes in integrated circuits designed for data memory and related functions, emphasizing low-power data storage solutions. Its activities encompass research and development, design, production, and sales of these integrated circuits, catering to various industry users.
Tongxin Medical Equipment
Series D in 2022
Tongxin makes magnetically-suspended artificial blood pumps which are designed to replace the human heart. They are undergoing clinical trials in China after being fast-tracked through the approval process by the National Medical Products Administration, state-run Xinhua News Agency
NeoCura
Series A in 2021
NeoCura is a biotechnology company based in Shenzhen, China, founded in 2017. It specializes in developing artificial intelligence-based platforms and diagnostic tests aimed at improving cancer treatment and diagnosis. The company's key offerings include NeoCura AI ALPINE, which predicts tumor neoantigen candidates; NeoCura AI EVEREST, designed for validating these neoantigens to enhance patient outcomes; NeoCura TP, an intelligent companion diagnostics tool that forecasts treatment options for immunotherapy; and NeoCura Ag, an AI-enabled immunotherapy that targets patient-specific neoantigens. Additionally, NeoCura provides diagnostic and medical laboratory services, leveraging AI to collect and analyze molecular biology and clinical data for better decision-making by healthcare professionals.
Vastai Technologies
Series B in 2021
Vastai Technologies specializes in the development of semiconductor chips tailored for computer vision, video processing, and various artificial intelligence applications. The company's innovative products are designed to enhance computing power for AI visual tasks, allowing manufacturers of computer devices to integrate advanced chip technology into their offerings. By focusing on the optimization of AI capabilities, Vastai Technologies aims to support the growing demand for efficient and powerful processing solutions in the tech industry.
Weishi Energy
Series A in 2021
Weishi Energy is a hydrogen fuel cell product research and development manufacturer, focusing on the market operation of hydrogen fuel cell technology, and is committed to promoting the low-carbon sustainable development of human energy. It is mainly engaged in the research and development, production and sales of hydrogen fuel cell products. At present, Weishi Energy has deployed five R&D centers in Shanghai, Baoding, Japan, Germany, and Canada. It has established a culturally diverse and technologically advanced R&D team, and strictly follows the V model development process to create vehicle-level fuel cell power systems and components. The company's main products include fuel cell engines, electric stacks, 35MPa/70MPa on-board hydrogen systems, bottle valves and pressure reducing valves, etc.
SVOLT
Series B in 2021
SVOLT manufacturer of electric batteries. They specialize in the manufacturing of automotive power batteries and energy storage systems. Their market applications include passenger cars, commercial vehicles, energy storage, and light power solutions. Their products include batteries and energy storage batterie. They provide users with energy vehicle charging piles, batteries recycling, and solutions.
METiS Pharmaceuticals
Series A in 2021
Jitai Medicine (METiS) is a biotechnology company that uses artificial intelligence to drive drug delivery and drug discovery. It combines advanced technologies like artificial intelligence, machine learning, and quantum simulation to achieve more effective design of innovative delivery materials, drug candidate selection and formulation design, "programmable nucleic acid drug" development, and nucleic acid delivery design.
Jenscare Biotech
Venture Round in 2021
Ningbo Jenscare Scientific develops solutions around structural heart disease that include the treatment of the tricuspid valve, mitral valve, aortic valve, and heart failure. The company's contact information is its physical address.
GeneQuantum Healthcare
Series C in 2021
GeneQuantum Healthcare (Suzhou) Co., Ltd. is a high-tech company specializing in the research and development of innovative biotherapeutics, particularly in the field of anti-tumor therapies. Founded in August 2013 in Suzhou Industrial Park, the company has established a world-class bio-conjugation technology platform that utilizes a ligase-dependent conjugation method. This advanced technology significantly enhances the therapeutic window for developing a series of next-generation Antibody-Drug-Conjugates (ADCs). GeneQuantum is actively working on advancing its ADC candidates towards Investigational New Drug (IND) applications in both the United States and China, while also focusing on expanding its product pipeline to address unmet medical needs in cancer treatment.
Abogen Biosciences
Series B in 2021
Abogen Biosciences, established in 2019 and headquartered in Jiangsu, China, specializes in the development of nucleic acid-based therapeutics, including RNA and DNA treatments, for combating cancer and infectious diseases.
XtalPi Technology
Series C in 2020
XtalPi Inc. is a pharmaceutical technology company that focuses on digital drug development solutions, leveraging quantum mechanics and artificial intelligence to enhance the efficiency of drug research and development. Founded in 2014 by a group of quantum physicists at MIT, the company has developed its Intelligent Digital Drug Discovery and Development (ID4) platform, which integrates advanced cloud computing algorithms to aid pharmaceutical firms in critical stages of drug R&D. XtalPi offers various tools, including XtalForc for visual force field calculations, XtalVision for crystal structure predictions, and Renova for platform support of its AI research initiatives. Its comprehensive services encompass crystal structure determination, solid-state testing, small molecule drug design, and collaborations in antibody and peptide research. Based in Cambridge, Massachusetts, with additional offices in China, XtalPi has established strategic partnerships with leading international pharmaceutical companies, demonstrating the broad applicability and recognition of its innovative technologies across the pharmaceutical value chain.
Care Link
Series A in 2020
Yijia follows the development model of "integration of medical care, health care, and health care," draws lessons from the mainstream model of mature compound health services in developed countries, implements the concept of "health care for every Chinese family," and focuses on professional medical-level services, nursing, rehabilitation, and elderly care, integrating diverse resources, and providing high-quality care.
MLog Tianqijia
Series B in 2018
MLog Tianqijia is based in Wuhan, China, and operates a commercial weather service platform. The company leverages meteorological forecast technology and big data to deliver a range of meteorological services to its users. By integrating advanced forecasting techniques with data analytics, MLog Tianqijia aims to provide accurate and timely weather information to meet the needs of various stakeholders.
New Flow Technology
Series A in 2018
New Flow Technology is a big data company focused on serving the financial industry. It offers a data-as-a-service platform that includes the DRCP data risk control platform. This technology enables banks, insurance companies, and other financial institutions to access accurate data, which facilitates improved strategic decision-making. By providing reliable data solutions, New Flow Technology aims to enhance operational efficiency and risk management for its clients.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.